Burosumab

Trade Name: 
Crysvita
Manufacturer/Distributor: 
Kyowa Kirin Limited
www.kyowa-kirin.com
Innomar Strategies (Distributor)
Classification: 
Fibroblast growth factor 23 (FGF23) Inhibitor
ATC Class: 
M05BX05 - Burosumab
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2018/12/05
Date Marketed in Canada (yyyy/mm/dd): 
2018/12/05
Presentation: 
Injection: 10 mg/mL. DIN: 02483629
Injection: 20 mg/mL. DIN: 02483637
Injection: 30 mg/mL. DIN: 02483645
Comments: 
Subcutaneous injection for treatment of X-linked hypophosphataemia (XLH) in adult and pediatric patients 1 year of age and older. Treatment should be initiated and monitored by a health professional experienced in the management of patients with metabolic bone diseases.
Source: 
Product monograph